Literature DB >> 26700183

Prevalence, distribution and clinical correlates of myocardial fibrosis in systemic lupus erythematosus: a cardiac magnetic resonance study.

M G Seneviratne1, S M Grieve2, G A Figtree3, R Garsia4, D S Celermajer5, S Adelstein4, R Puranik6.   

Abstract

OBJECTIVES: To assess the prevalence, distribution and clinical correlates of myocardial fibrosis, as detected by cardiac magnetic resonance (CMR), in systemic lupus erythematosus (SLE).
METHODS: Forty-one subjects (average age 39 ± 12 years and 80% female) with SLE underwent CMR imaging at 1.5T, using late gadolinium enhancement (LGE) to quantify the area of myocardial fibrosis in the left ventricle (LV). Subjects also underwent transthoracic echocardiography (TTE) and exercise testing.
RESULTS: LGE was detected in 15/41 subjects, 11 with localized LGE (<15% LV mass) and four with extensive LGE (>15% LV mass). The commonest site of LGE was the interventricular septum, with all but one case demonstrating an intramural or inflammatory pattern. The mean age of the >15% LGE group (55 ± 15 years) was significantly higher than the <15% or absent LGE subgroups. Based on both CMR and TTE measurements, subjects with LGE > 15% demonstrated a reduced E/A ratio of 0.9 ± 0.4 relative to the <15% and absent LGE subgroups. LV end-systolic volume (ESVi), end-diastolic volume (EDVi) and maximum exercise capacity were also reduced in the >15% LGE group.
CONCLUSIONS: Mid-wall myocardial fibrosis occurs frequently in SLE and is strongly associated with advancing subject age, but not with SLE duration or severity. Extensive LGE may be associated with diastolic dysfunction and impaired exercise capacity, although this may be an epiphenomenon of age. Cardiac magnetic resonance with quantitative assessment of LGE may provide a basis for cardiac risk stratification in SLE.
© The Author(s) 2015.

Entities:  

Keywords:  Systemic lupus erythematosus; cardiovascular disease; magnetic resonance imaging

Mesh:

Substances:

Year:  2015        PMID: 26700183     DOI: 10.1177/0961203315622275

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  6 in total

1.  TLR7 Activation Accelerates Cardiovascular Pathology in a Mouse Model of Lupus.

Authors:  Ahmed S Elshikha; Xiang Yu Teng; Nathalie Kanda; Wei Li; Seung-Chul Choi; Georges Abboud; Morgan Terrell; Kristianna Fredenburg; Laurence Morel
Journal:  Front Immunol       Date:  2022-07-04       Impact factor: 8.786

2.  Assessment of aortic stiffness in patients with ankylosing spondylitis using cardiovascular magnetic resonance.

Authors:  P Stefan Biesbroek; Sjoerd C Heslinga; Peter M van de Ven; Mike J L Peters; Raquel P Amier; Thelma C Konings; Christopher D Maroules; Colby Ayers; Parag H Joshi; Irene E van der Horst-Bruinsma; Vokko P van Halm; Albert C van Rossum; Michael T Nurmohamed; Robin Nijveldt
Journal:  Clin Rheumatol       Date:  2018-05-12       Impact factor: 2.980

Review 3.  Role of Cardiac Magnetic Resonance in the Diagnosis and Prognosis of Nonischemic Cardiomyopathy.

Authors:  Amit R Patel; Christopher M Kramer
Journal:  JACC Cardiovasc Imaging       Date:  2017-10

4.  Vascular Inflammation in Mouse Models of Systemic Lupus Erythematosus.

Authors:  Holly Ryan; Laurence Morel; Erika Moore
Journal:  Front Cardiovasc Med       Date:  2022-03-28

5.  The heart in systemic lupus erythematosus - A comprehensive approach by cardiovascular magnetic resonance tomography.

Authors:  Thilo Burkard; Marten Trendelenburg; Thomas Daikeler; Christoph Hess; Jens Bremerich; Philip Haaf; Peter Buser; Michael J Zellweger
Journal:  PLoS One       Date:  2018-10-01       Impact factor: 3.240

Review 6.  Cardiovascular disease in women: insights from magnetic resonance imaging.

Authors:  Chiara Bucciarelli-Ducci; Ellen Ostenfeld; Lauren A Baldassarre; Vanessa M Ferreira; Luba Frank; Kimberly Kallianos; Subha V Raman; Monvadi B Srichai; Elisa McAlindon; Sophie Mavrogeni; Ntobeko A B Ntusi; Jeanette Schulz-Menger; Anne Marie Valente; Karen G Ordovas
Journal:  J Cardiovasc Magn Reson       Date:  2020-09-28       Impact factor: 5.364

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.